JNJ 42847922

Drug Profile

JNJ 42847922

Alternative Names: JNJ-922; JNJ42847922; MIN 202

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class Antidepressants; Sleep disorder therapies
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia
  • Phase I Major depressive disorder

Most Recent Events

  • 31 May 2017 Minerva plans three phase IIb trials for Major depressive disorder and Insomnia
  • 27 Feb 2017 Janssen Research & Development completes a phase I trial in Healthy volunteers in USA (NCT03025022)
  • 17 Jan 2017 Janssen Research & Development initiates a phase I trial in Healthy volunteers in USA (NCT03025022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top